The U.S. risks losing a once-decisive edge over China in biotechnology unless the federal government prioritizes the sector’s advancement with new funding and policies, a bipartisan commission warned in a

美国两党委员会警告称，除非联邦政府通过新的资金和政策优先推动生物技术领域的发展，否则美国可能失去在生物技术方面对中国曾经决定性的优势。

report issued Tuesday

周二发布的报告

.

。

At minimum, the commission wrote, the U.S. should invest at least $15 billion over the next five years to strengthen the country’s biotech capabilities. It also called for a more “proactive” government strategy, including the establishment of a new National Biotechnology Coordination Office within the White House..

报告写道，至少美国应该在未来五年内投资至少1500亿美元，以加强国家的生物技术能力。报告还呼吁采取更“积极”的政府战略，包括在白宫内设立一个新的国家生物技术协调办公室。

“China is quickly ascending to biotechnology dominance, having made biotechnology a strategic priority for 20 years,” the report states. “To remain competitive, the United States must take swift action in the next three years. Otherwise, we risk falling behind, a setback from which we may never recover.”.

“中国正在迅速走向生物技术领域的主导地位，并且已经将生物技术作为战略重点发展了20年，”报告指出。“为了保持竞争力，美国必须在接下来的三年内迅速采取行动。否则，我们可能面临落后风险，这种落后可能会让我们永远无法恢复。”

The report was authored by the National Security Commission on Emerging Biotechnology, which was established by Congress through defense appropriations legislation in 2022. Made up of 11 members, including lawmakers from both parties, the commission has spent the past two years studying the state of biotechnology competition between the U.S.

该报告由国会通过2022年国防拨款立法成立的新兴生物技术国家安全委员会撰写。该委员会由11名成员组成，包括两党的立法者，过去两年一直在研究美中之间生物技术竞争的现状。

and other countries, particularly China. Its recommendations are meant to provide the foundation for legislation, much as work by an earlier commission helped pave the way for the 2022 CHIPS Act, which was aimed at semiconductor manufacturing and research. .

和其他国家，尤其是中国。其建议旨在为立法提供基础，正如早前一个委员会的工作帮助铺平了2022年《芯片法案》的道路一样，该法案旨在推动半导体制造和研究。

“The United States is locked in a competition with China that will define the coming century,” said commission chair and Senator Todd Young, R-Ind., in a statement on the report’s release. “Biotechnology is the next phase in that competition.”

“美国正与中国陷入一场将定义未来百年的竞争，”委员会主席、印第安纳州共和党参议员托德·杨在报告发布时的声明中表示。“生物技术是这场竞争的下一阶段。”

Young and the rest of the commission take alarm at the rapid acceleration of China’s biotech capabilities, which they ascribe to its government’s industrial policies as well as to the advent of new artificial intelligence tools that China has adopted quickly.

杨和其他委员会成员对中国生物技术能力的迅速提升感到担忧，他们将其归因于中国政府的产业政策以及中国迅速采用新的人工智能工具。

They cite the strength of Chinese companies like WuXi AppTec, a contract manufacturer targeted in

他们提到了像药明康德这样被针对的中国合同制造商的实力，

legislation

立法

that was proposed but ultimately dropped last year. And they warn that the Chinese government’s close involvement in biotech could lead to policies designed to strategically weaken the U.S.

这是去年提出但最终被否决的提案。他们警告称，中国政府对生物技术的密切参与可能导致旨在战略性削弱美国的政策。

“We must not treat Chinese state-run companies as ordinary competitors in our market, even if it means using more expensive alternatives,” the report states.

“报告指出：‘我们绝不能将中国的国有企业视为我们市场中的普通竞争对手，即使这意味着使用更昂贵的替代品’”。

In response, the commission detailed dozens of recommendations to bolster U.S. biotech. Notably, it calls for Congress to establish an “Independence Investment Fund” to support new startups, as well as to direct the development of a network of precommercial bioindustrial manufacturing facilities.

作为回应，该委员会详细列出了数十条加强美国生物技术的建议。特别是，它呼吁国会设立一个“独立投资基 金”以支持新创企业，并指导建立一个准商业生物工业制造设施网络。

It also recommends outbound investment rules to “ensure that U.S. capital does not support Chinese development” of biotechnologies that come with national security risks. Such rules could potentially complicate U.S. companies’

它还建议制定对外投资规则，以“确保美国资本不会支持中国带来国家安全风险的生物技术发展”。此类规则可能会使美国公司的处境复杂化。

licensing of experimental new drugs developed by Chinese firms

由中国公司开发的实验性新药的许可

, although the report doesn’t specifically suggest barring these kind of deals.

，尽管报告并没有特别建议禁止此类交易。

Yet the commission’s call for greater biotech investment comes at a moment when the Trump administration has ordered drastic cuts to research funding and sweeping layoffs across agencies that oversee biotech regulation, most prominently at the Food and Drug Administration. And the commissioners urge the U.S.

然而，该委员会呼吁加大生物技术投资之际，特朗普政府却下令大幅削减研究资金，并在监管生物技术的各机构，尤其是食品和药物管理局，进行大规模裁员。并且，委员们敦促美国。

to leverage its ability to attract talented scientists to its “open innovation ecosystem” just as the administration has sparked widespread alarm in academia by revoking student visas and targeting universities. .

利用其吸引优秀科学家进入“开放创新生态系统”的能力，就像政府通过撤销学生签证和针对大学在学术界引发广泛警报一样。

U.S. companies are also watching carefully to see whether the Trump administration targets pharmaceuticals with sector-specific tariffs. The sector was exempted from the new duties President Donald Trump rolled out April 2, but taxing imports could be part of White House efforts to spur investment in U.S.

美国公司也在密切关注特朗普政府是否会针对制药行业征收特定行业的关税。该行业被排除在总统唐纳德·特朗普4月2日推出的新关税之外，但对进口产品征税可能是白宫推动美国投资努力的一部分。

biomanufacturing. .

生物制造。

“The pharmaceutical companies are going to come roaring back,” Trump said in a White House address on April 2, during which he cited recent investments by Eli Lilly and Johnson & Johnson to build new U.S. plants.

“制药公司将会强势回归，”特朗普在4月2日的白宫讲话中表示，期间他提到了礼来和强生近期为建造新美国工厂的投资。